Loading...
•
Sep 30, 2024
ACADIA Q3 2024 Earnings Report
Reported financial results for the third quarter of 2024, highlighted by revenue growth and progress in commercial and pipeline initiatives.
Key Takeaways
Acadia Pharmaceuticals reported a successful third quarter in 2024, with total revenues of $250.4 million, reflecting an 18% increase year-over-year. The company is on track to achieve over $1 billion in annualized sales in 2025, driven by the growth of NUPLAZID and DAYBUE.
Total revenues reached $250.4 million, an 18% increase compared to the third quarter of 2023.
NUPLAZID net product sales were $159.2 million, representing a 10% year-over-year increase.
DAYBUE net product sales amounted to $91.2 million, a 36% increase compared to the same period last year.
Net income for the quarter was $32.8 million, or $0.20 per common share, a significant improvement from the net loss of $65.2 million in the third quarter of 2023.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.comDAYBUE Sales Revenue
CapyFin.com Forward Guidance
Acadia is updating its 2024 guidance.
Positive Outlook
- NUPLAZID net product sales guidance is narrowed to the high end of the prior range and is now expected to be $600 to $610 million.
- DAYBUE net product sales guidance is narrowed to the low end of the prior range and is now expected to be $340 to $350 million.
- Total revenue guidance is revised to a range of $940 to $960 million.
- R&D expense guidance is lowered and is now expected to be between $280 to $290 million.
Challenges Ahead
- SG&A expense guidance is increased and is now expected to be between $480 to $495 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income